Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2

被引：9

作者：

Jeselsohn, Rinath ^{[1
,2
,3
]}

Schiff, Rachel ^{[4
,5
]}

Grinshpun, Albert ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Breast Oncol Ctr, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA

[4] Baylor Coll Med, Dept Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

来源：

CANCER CELL | 2021年 / 39卷 / 10期

关键词：

D O I：

10.1016/j.ccell.2021.08.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overcoming resistance to CDK4/6 inhibitors is a major clinical challenge. In this issue of Cancer Cell, Freeman-Cook et al. study mechanisms of resistance to CDK4/6 inhibitors by employing a CRISPRa screen. They identify the cyclin E-CDK2 axis and Myc signaling as key pathways of resistance and develop PF-06873600, a selective CDK2/4/6 inhibitor.

引用

页码：1302 / 1305

页数：5

共 50 条

[21] Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, Charles J.
Beach, David
Shapiro, Geoffrey I.
CANCER DISCOVERY, 2016, 6 (04) : 353 - 367
[22] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
Pandey, Kamal
CANCER RESEARCH, 2020, 80 (16)
[23] Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Freeman-Cook, Kevin
Hoffman, Robert
Miller, Nichol
Almaden, Jonathan
Chionis, John
Zhang, Qin
Eisele, Koleen
Liu, Chaoting
Zhang, Cathy
Huser, Nanni
Nguyen, Lisa
Costa-Jones, Cinthia
Niessen, Sherry
Carelli, Jordan
Lapek, John
Weinrich, Scott
Wei, Ping
McMillan, Elizabeth
Wilson, Elizabeth
Wang, Tim
McTigue, Michele
Ferre, Rose
He, You-Ai
Ninkovic, Sacha
Behenna, Douglas
Tran, Khanh
Sutton, Scott
Nagata, Asako
Ornelas, Martha
Kephart, Susan
Zehnder, Luke
Murray, Brion
Xu, Meirong
Solowiej, James
Visswanathan, Ravi
Boras, Britton
Looper, David
Lee, Nathan
Bienkowska, Jadwiga
Zhu, Zhou
Kan, Zhengyan
Ding, Ying
Mu, Xinmeng
Oderup, Cecilia
Salek-Ardakani, Shahram
White, Michael
VanArsdale, Todd
Dann, Stephen
CANCER CELL, 2021, 39 (10) : 1404 - +
[24] CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets
Zhang, Wengang
Liu, Yonglan
Jang, Hyunbum
Nussinov, Ruth
JACS AU, 2024, 4 (05): : 1911 - 1927
[25] CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
Kim, Sungsoo
Leong, Alessandra
Kim, Minah
Yang, Hee Won
SCIENTIFIC REPORTS, 2022, 12 (01)
[26] Targeting CDK4/6 reorganizes chromatin
Hurtado, Antoni
NATURE CANCER, 2021, 2 (01) : 16 - 17
[27] Granulosa cell cycle during the periovulatory interval and the role of cyclin D2, CDK2, and CDK4 in the rat.
Cannon, JD
Cherian-Shaw, M
Chaffin, CL
BIOLOGY OF REPRODUCTION, 2003, 68 : 228 - 228
[28] Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity
Henri, P.
Prevel, C.
Pellerano, M.
Lacote, J.
Stoebner, P.
Morris, M.
Meunier, L. L.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S254 - S254
[29] CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition
Sungsoo Kim
Alessandra Leong
Minah Kim
Hee Won Yang
Scientific Reports, 12
[30] Targeting CDK4/6 reorganizes chromatin
Antoni Hurtado
Nature Cancer, 2021, 2 : 16 - 17

← 1 2 3 4 5 →